Unknown

Dataset Information

0

Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy.


ABSTRACT: BACKGROUND:Practical issues, including cost, hinder implementing virologic monitoring of patients on antiretroviral therapy (ART) in resource-limited settings. We evaluated factors that might guide monitoring frequency and efforts to prevent treatment failure after initial virologic suppression. METHODS:Participants were the 911 HIV-infected antiretroviral-naïve adults with CD4 count <300 cells/?L who started efavirenz-based ART in the international A5175/PEARLS trial and achieved HIV-1 RNA <1000 copies/mL at 24 weeks. Participant report of ART adherence was evaluated using a structured questionnaire in monthly interviews. Adherence and readily available clinical and laboratory measures were evaluated as predictors of late virologic failure (late VF: confirmed HIV-1 RNA ?1000 copies/mL after 24 weeks). RESULTS:During median follow-up of 3.5 years, 82/911 participants (9%) experienced late VF. Of 516 participants reporting missed doses during the first 24 weeks of ART, 55 (11%) experienced late VF, compared with 27 (7%) of 395 participants reporting no missed doses (hazard ratio: 1.73; 95% CI: 1.08, 2.73). This difference persisted in multivariable analysis, in which lower pre-ART hemoglobin and absence of Grade ?3 laboratory results prior to week 24 were also associated with higher risk of late VF. DISCUSSION:In this clinical trial, the late VF rate after successful suppression was very low. If achievable in routine clinical practice, virologic monitoring involving infrequent (e.g. annual) measurements might be considered; the implications of this for development of resistance need evaluating. Patients reporting missed doses early after ART initiation, despite achieving initial suppression, might require more frequent measurement and/or strategies for promoting adherence.

SUBMITTER: Singini I 

PROVIDER: S-EPMC5276794 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Predictors of late virologic failure after initial successful suppression of HIV replication on efavirenz-based antiretroviral therapy.

Singini Isaac I   Campbell Thomas B TB   Smeaton Laura M LM   Kumarasamy Nagalingeswaran N   La Rosa Alberto A   Taejareonkul Sineenart S   Safren Steven A SA   Flanigan Timothy P TP   Hakim James G JG   Hughes Michael D MD  

HIV clinical trials 20160729 5


<h4>Background</h4>Practical issues, including cost, hinder implementing virologic monitoring of patients on antiretroviral therapy (ART) in resource-limited settings. We evaluated factors that might guide monitoring frequency and efforts to prevent treatment failure after initial virologic suppression.<h4>Methods</h4>Participants were the 911 HIV-infected antiretroviral-naïve adults with CD4 count <300 cells/μL who started efavirenz-based ART in the international A5175/PEARLS trial and achieved  ...[more]

Similar Datasets

| S-EPMC5384719 | biostudies-literature